Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody

We report the first case of a 32-year-old woman with Muckle–Wells syndrome and biopsy-proven systemic AA amyloidosis and end-stage renal disease. She was treated with canakinumab 150 mg subcutaneously every 8 weeks and underwent renal transplantation. Fourteen months after renal transplanation, the patient had no flares of Muckle–Wells syndrome and no evidence of amyloidosis in the renal transplant under an excellent graft function and therapy with canakinumab.